-DOCSTART- -X- O
Leptospirosis -X- _ B-Patient
is -X- _ O
the -X- _ O
most -X- _ O
widespread -X- _ O
zoonotic -X- _ O
disease -X- _ O
, -X- _ O
estimated -X- _ O
to -X- _ O
cause -X- _ O
severe -X- _ O
infection -X- _ O
in -X- _ O
more -X- _ O
than -X- _ O
one -X- _ O
million -X- _ O
people -X- _ O
each -X- _ O
year -X- _ O
, -X- _ O
particularly -X- _ O
in -X- _ O
developing -X- _ O
countries -X- _ O
of -X- _ O
tropical -X- _ O
areas. -X- _ O
Several -X- _ O
factors -X- _ O
such -X- _ O
as -X- _ O
variable -X- _ O
and -X- _ O
nonspecific -X- _ O
clinical -X- _ O
manifestation -X- _ O
, -X- _ O
existence -X- _ O
of -X- _ O
large -X- _ O
number -X- _ O
of -X- _ O
serovars -X- _ O
and -X- _ O
asymptomatic -X- _ O
hosts -X- _ O
spreading -X- _ O
infection -X- _ O
, -X- _ O
poor -X- _ O
sanitation -X- _ O
and -X- _ O
lack -X- _ O
of -X- _ O
an -X- _ O
effective -X- _ O
vaccine -X- _ O
make -X- _ O
prophylaxis -X- _ O
difficult. -X- _ O
Consequently -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
develop -X- _ O
an -X- _ O
effective -X- _ O
vaccine -X- _ O
to -X- _ O
halt -X- _ O
its -X- _ O
spread -X- _ O
all -X- _ O
over -X- _ O
the -X- _ O
world. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
an -X- _ O
immunoinformatics -X- _ O
approach -X- _ O
was -X- _ O
employed -X- _ O
to -X- _ O
identify -X- _ O
the -X- _ O
most -X- _ O
vital -X- _ O
and -X- _ O
effective -X- _ O
immunogenic -X- _ B-Intervention
protein -X- _ I-Intervention
from -X- _ I-Intervention
the -X- _ I-Intervention
proteome -X- _ I-Intervention
of -X- _ I-Intervention
Leptospira -X- _ I-Intervention
interrogans -X- _ I-Intervention
serovar -X- _ I-Intervention
Copenhageni -X- _ I-Intervention
strain -X- _ I-Intervention
L1-130 -X- _ I-Intervention
that -X- _ O
may -X- _ O
be -X- _ O
suitable -X- _ O
to -X- _ O
stimulate -X- _ O
a -X- _ O
significant -X- _ O
immune -X- _ O
response -X- _ O
aiding -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
peptide -X- _ O
vaccine -X- _ O
against -X- _ O
leptospirosis. -X- _ B-Patient
Both -X- _ O
B-cell -X- _ O
and -X- _ O
T-cell -X- _ O
( -X- _ O
Helper -X- _ O
T-lymphocyte -X- _ O
( -X- _ O
HTL -X- _ O
) -X- _ O
and -X- _ O
cytotoxic -X- _ O
T -X- _ O
lymphocyte -X- _ O
( -X- _ O
CTL -X- _ O
) -X- _ O
) -X- _ O
epitopes -X- _ O
were -X- _ O
predicted -X- _ O
for -X- _ O
the -X- _ O
conserved -X- _ O
and -X- _ O
most -X- _ O
immunogenic -X- _ O
outer -X- _ O
membrane -X- _ O
lipoprotein. -X- _ O
Further -X- _ O
, -X- _ O
the -X- _ O
binding -X- _ O
interaction -X- _ O
of -X- _ O
CTL -X- _ O
epitopes -X- _ O
with -X- _ O
Major -X- _ O
Histocompatibility -X- _ O
Complex -X- _ O
class -X- _ O
I -X- _ O
( -X- _ O
MHC-I -X- _ O
) -X- _ O
was -X- _ O
evaluated -X- _ O
using -X- _ O
docking -X- _ O
techniques. -X- _ O
A -X- _ O
Molecular -X- _ O
Dynamics -X- _ O
Simulation -X- _ O
study -X- _ O
was -X- _ O
also -X- _ O
performed -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
stability -X- _ O
of -X- _ O
the -X- _ O
resulting -X- _ O
epitope-MHC-I -X- _ O
complexes. -X- _ O
Overall -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
provides -X- _ O
novel -X- _ O
vaccine -X- _ O
candidates -X- _ O
and -X- _ O
may -X- _ O
prompt -X- _ O
further -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
against -X- _ O
leptospirosis -X- _ B-Patient
. -X- _ O

